The short version of bremelanotide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-06 and is reviewed periodically as new material appears.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
| Property | Value | Notes |
|---|---|---|
| Primary receptor targets | MC4R and MC1R | Agonist activity; MC3R and MC5R weaker |
| Route studied in trials | Subcutaneous injection | Intranasal form was not approved |
| Elimination half-life | Approximately 2–3 hours | Short relative to the dosing interval |
| Common analytical method | Liquid chromatography–tandem mass spectrometry | Used for peptide quantification in plasma |
| Reported adverse events | Nausea, flushing, headache | Transient blood pressure rise also noted |
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
The practical role of protein structure prediction is now more important than ever. Massive amounts of protein sequence data are produced by modern large-scale DNA sequencing efforts such as the Human Genome Project. Despite community-wide efforts in structural genomics, the output of experimentally determined protein structures—typically by time-consuming and relatively expensive X-ray crystallography or NMR spectroscopy—is lagging far behind the output of protein sequences. The protein structure prediction remains an extremely difficult and unresolved undertaking. The two main problems are the calculation of protein free energy and finding the global minimum of this energy. A protein structure prediction method must explore the space of possible protein structures which is astronomically large. These problems can be partially bypassed in "comparative" or homology modeling and fold recognition methods, in which the search space is pruned by the assumption that the protein in question adopts a structure that is close to the experimentally determined structure of another homologous protein. In contrast, the de novo protein structure prediction methods must explicitly resolve these problems. The progress and challenges in protein structure prediction have been reviewed by Zhang.
Δp is the pressure difference between the two ends, L is the length of pipe, μ is the dynamic viscosity, Q is the volumetric flow rate, R is the pipe radius, A is the cross-sectional area of pipe. The equation does not hold close to the pipe entrance. The equation fails in the limit of low viscosity, wide and/or short pipe. Low viscosity or a wide pipe may result in turbulent flow, making it necessary to use more complex models, such as the Darcy–Weisbach equation. The ratio of length to radius of a pipe should be greater than 1/48 of the Reynolds number for the Hagen–Poiseuille law to be valid. If the pipe is too short, the Hagen–Poiseuille equation may result in unphysically high flow rates; the flow is bounded by Bernoulli's principle, under less restrictive conditions, by
Watson had a good start to the 2014 season, but he injured his hip flexor in round 12 and consequently missed ten weeks. Watson later returned to play in the final three games of the home-and-away season and Essendon's elimination final loss to North Melbourne. Watson then went on to poll eight Brownlow votes, behind up-and-coming midfielder and future captain Dyson Heppell. Watson was also selected in the Australian team for the first time in his career to play in the 2014 International Rules Series. Watson was among the best players in the one-test series, which Australia won by ten points. In 2015, despite controversy surrounding the team's lack of fitness (following a compromised pre-season) and a tough first half of the season for Essendon, Watson continued to lead his team well early in the season despite his own injury clouds. In Round 14, Watson played his 200th AFL game in what proved to be a torrid day for the Bombers, as they lost to St Kilda by 110 points. Following that match, Watson was ruled out for the rest of the season with a shoulder injury, having injured it the previous week; Watson polled seven Brownlow votes in the first five rounds prior to the injury. He was later banned for the 2016 season as part of the club's supplements saga. Watson played his first competitive match in over eighteen months – and his first without being captain of the club since 2009 – when he and several of the other Essendon players who served bans in 2016 made their return to the field against Collingwood in the 2017 pre-season.
==== Promethazine ==== Promethazine is one of the recommended drugs by NASA to treat space motion sickness and studies have been conducted to analyze their pharmacological responses in outer space. Studies on promethazine were performed exclusively on Earth, called earthbound models, stimulating microgravity and weightlessness through forty-eight hours of bed rest. The −6° head-down best rest model, where individuals are placed lying 6 degrees down to study weightlessness. This type of model simulates the shift in fluid from the bottom to the top of the body, as well as bone loss, found in astronauts in weightless environments. Using twelve volunteers, 50 mg of promethazine was delivered orally or intramuscularly to the deltoid muscle before and after forty-eight hours of bedrest. Blood was examined at intervals of 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-drug deliverance and promethazine levels were detected using plasma promethazine assays, which uses liquid chromatography to quantify promethazine kinetics. The study determined that higher concentrations of promethazine were found in the blood through oral delivery and bioavailability factors was impacted through weightlessness.
== Honours == Du Vigneaud joined Alpha Chi Sigma while at the University of Illinois in 1930. He was elected to the United States National Academy of Sciences and the American Philosophical Society in 1944, and the American Academy of Arts and Sciences in 1948. He received the 1955 Nobel Prize in Chemistry "for his work on biochemically important sulphur compounds, especially for the first synthesis of a polypeptide hormone," a reference to his work on the peptide hormone oxytocin.
Sources: en.wikipedia.org
=== Wound repair === MMP9 is greatly upregulated during human respiratory epithelial healing. Using a MMP9 deficient mouse model, it was seen that MMP9 coordinated epithelial wound repair and deficient mice were unable to remove the fibrinogen matrix during wound healing. When interacting with TGF-ß1, Gelatinase B also stimulates collagen contraction, aiding in wound closure.
Gabapentin is a 3,3-disubstituted derivative of GABA. Therefore, it is a GABA analog, as well as a γ-amino acid. It is similar to several other compounds that collectively are called gabapentinoids. Specifically, it is a derivative of GABA with a pentyl disubstitution at the 3 position, hence, the name - gabapentin, in such a way as to form a six-membered ring. After the formation of the ring, the amine and carboxylic groups are not in the same relative positions as they are in the GABA; they are more conformationally constrained. Although it has been known for some time that gabapentin must bind to the α2δ-1 protein to act pharmacologically (see Pharmacodynamics), the three-dimensional structure of the α2δ-1 protein with gabapentin bound (or alternatively, the native amino acid, L-Isoleucine bound) has only recently been obtained by cryo-electron microscopy. A figure of this drug-bound structure is shown in the Chemistry section of the entry on gabapentinoid drugs. This study confirms other findings to show that both compounds alternatively can bind at a single extracellular site (somewhat distant from the calcium conducting pore of the voltage-gated calcium channel α1 subunit) on the calcium channel and chemotaxis domain of α2δ-1.
In December 2017, he signed Tax Reform for Acceleration and Inclusion Law (TRAIN Law) which excludes those earning an annual taxable income of ₱250,000 and below from paying the personal income tax, while raising higher excise taxes on vehicles, sugar-sweetened beverages, petroleum products, tobacco and other non-essential goods. Revenues collected from the TRAIN law will help fund the administration's massive infrastructure program. In March 2021, to attract more investments and maintain fiscal stability, Duterte signed the Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act, reducing the 30 percent corporate income tax rate to 25 percent for firms with assets above ₱100 million and to 20 percent for smaller firms. Duterte raised sin taxes on tobacco and vapor products in July 2019, and alcohol beverages and electronic cigarettes in January 2020, to fund the Universal Health Care Act and reduce incidence of deaths and diseases associated with smoking and alcohol consumption. Duterte's tax reform program has garnered both support and criticism. Critics have argued that the administration's tax policy would burden the poor. The implementation of the TRAIN Law triggered protests from various left-wing groups. On January 15, 2018, protesters gathered at various public market sites, calling for the revocation of TRAIN. However, proponents of the program cite its appeal to foreign investors and economic benefits as the main reasons behind tax reform.
Ampika Pickston (born 23 July 1981) is an English model, reality TV star and business owner. She starred in The Real Housewives of Cheshire from 2015 to 2017. Pickston is the CEO of Ampika's Aesthetics, a training school based in Hale, Greater Manchester, which teaches aesthetic procedures.
=== Tuberoinfundibular dopaminergic neurons === The cell bodies of TIDA neurons are located in the arcuate nucleus (infundibular nucleus) of the mediobasal hypothalamus. Their axons project to the external zone of the median eminence, where dopamine is released into the fenestrated capillaries of the primary portal plexus. First identified by Kjell Fuxe in 1963–1964, TIDA neurons are distinguished from nigrostriatal and mesolimbic dopamine populations by their neuroendocrine function. TIDA neurons display intrinsic oscillatory activity and are regulated by gonadal steroids and by prolactin itself.
Sources: en.wikipedia.org
The South African Defence Force (SADF) (Afrikaans: Suid-Afrikaanse Weermag) comprised the armed forces of South Africa from 1957 until 1994. Shortly before the state reconstituted itself as a republic in 1961, the former Union Defence Force was officially succeeded by the SADF, which was established by the Defence Act (No. 44) of 1957. The SADF, in turn, was superseded by the South African National Defence Force in 1994.
== Structure == Like other amino acids (not as a residue of a protein), cysteine exists as a zwitterion. Cysteine has l chirality in the older d/l notation based on homology to d- and l-glyceraldehyde. In the newer R/S system of designating chirality, based on the atomic numbers of atoms near the asymmetric carbon, cysteine (and selenocysteine) have R chirality, because of the presence of sulfur (or selenium) as a second neighbor to the asymmetric carbon atom. The remaining chiral amino acids, having lighter atoms in that position, have S chirality. Replacing sulfur with selenium gives selenocysteine.
=== D11AH Agents for dermatitis, excluding corticosteroids === D11AH01 Tacrolimus D11AH02 Pimecrolimus D11AH03 Cromoglicic acid D11AH04 Alitretinoin D11AH05 Dupilumab D11AH06 Crisaborole D11AH07 Tralokinumab D11AH08 Abrocitinib D11AH09 Ruxolitinib D11AH10 Lebrikizumab D11AH11 Delgocitinib D11AH12 Nemolizumab QD11AH90 Oclacitinib QD11AH91 Lokivetmab QD11AH92 Ilunocitinib QD11AH93 Atinvicitinib
Besides that, maintaining a prolonged strict oral hygiene through proper intrasulcular toothbrushing technique could promote the keratinisation of the sulcular epithelium through the elimination of the bacterial flora within the sulcus. However, the clinical significance of the keratinisation of sulcular epithelium remains questionable as its contribution to the strength of the semi-permeable barrier is minimal and inducing keratinisation is also suggested to interfere with the healing process in periodontitis or after surgery. Others also warn against keratinisation of the adjacent junctional epithelium which could compromise its attachment to the tooth, defeating its purpose as a physical barrier.
Sources: en.wikipedia.org
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.
Nausea, flushing, headache, and transient blood pressure elevation are the most frequently reported events. These typically appear shortly after dosing and are usually described as mild to moderate in severity. Safety data covering long periods of continuous use remain limited.
A short half-life means the compound clears from circulation within hours, so any effect is tied closely to dosing time. Accumulation between doses is therefore unlikely under the studied schedule. The practical consequence is that timing of administration shapes what observers record.
It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.